Related Experiment Video
Updated: Jul 6, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular
M Kyriakidis1, A Antonopoulos, E Georgiou
1Department of Cardiology, Hippokration Hospital, University of Athens, Greece.
Insights
Captopril improves cardiac performance in post-myocardial infarction patients with reduced ejection fraction. This study shows captopril, combined with standard therapy, enhances left ventricular function response to increased afterload, particularly in those with ejection fraction < 40%.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme inhibitors (ACEIs) show benefits in acute myocardial infarction (AMI).
- Limited data exist on ACEIs' effects on cardiac performance under increased afterload in AMI patients.
Purpose of the Study:
- To investigate the effects of captopril as adjuvant therapy on left ventricular performance in Q-wave AMI patients.
- To assess the impact of increased afterload on cardiac function in AMI patients treated with standard therapy versus captopril.
Main Methods:
- 77 consecutive Q-wave AMI patients were studied.
- Phenylephrine was administered to measure pre-ejection period/left ventricular ejection time ratio (PEP/LVET) on days 4 and 30.
- Patients were randomized to standard therapy alone or with captopril.
Main Results:
- Standard therapy alone led to significant left ventricular dysfunction after phenylephrine in patients with ejection fraction < 40%.
- Captopril adjuvant therapy improved PEP/LVET ratio between days 4 and 30 in patients with ejection fraction < 40%.
- No significant benefit was observed in patients with ejection fraction >= 40%.
Conclusions:
- PEP/LVET ratio response to increased afterload is a useful non-invasive marker for left ventricular dysfunction post-MI.
- Captopril adjuvant therapy improves left ventricular performance and heart rate response in asymptomatic Q-wave post-MI patients, especially those with ejection fraction < 40%.
Abstract:
A growing body of data support the beneficial effects of angiotensin-converting enzyme inhibitors in the prevention of cardiac enlargement and improvement of left ventricular function in patients with acute myocardial infarction. However, very little information exists about the direct effect of increased afterload on cardiac performance in these patients and the possible favourable effects of angiotensin-converting enzyme inhibitors as adjunctive treatment to thrombolysis, beta-blockers and nitrates. We have, therefore, studied the effects of captopril as adjuvant therapy to thrombolysis, beta-blockers and nitrates (standard therapy) on left ventricular performance in 77 consecutive patients with uncomplicated Q-wave acute myocardial infarction, by the measurement of the pre-ejection period/left ventricular ejection time ratio before and after (0.25-0.50 mg) phenylephrine administration on the 4th and 30th post-infarction days. Patients were randomized on day 4 either to continue standard therapy alone (group 1, 35 patients) or to receive oral captopril therapy (12.5 mg t.i.d.) in addition to standard therapy (group 2, 42 patients) in a double-blind parallel study. Among the patients of group 1 there was a significant deterioration of left ventricular function after phenylephrine administration. This was shown by an increase of pre-ejection period/left ventricular ejection time ratio only in the subset of patients with ejection fraction < 40%, as measured by contrast ventriculography, on both the 4th and 30th post-infarction days changing from 0.435 +/- 0.070 to 0.528 +/- 0.101, P < 0.01 and from 0.404 +/- 0.098 to 0.515 +/- 0.092, P < 0.02, respectively. In contrast there were no significant changes in patients with ejection fraction > or = 40%. Among patients of group 2, phenylephrine administration induced a significant increase, only on the 4th day, in pre-ejection period/left ventricular ejection time ratio only in the subset of patients with ejection fraction < 40% changing from 0.410 +/- 0.107 to 0.535 +/- 0.102, P < 0.01. In the remaining patients with ejection fraction > or = 40% there were no significant changes on either the 4th or 30th post-infarction days. Furthermore, a significant improvement was observed after phenylephrine administration in the pre-ejection period/left ventricular ejection time ratio between the 4th and 30th post-infarction days, which changed from 0.535 +/- 0.102 on day 4 to 0.368 +/- 0.052 on day 30 (P < 0.004). Also, a four-way ANOVA detected a significant reduction of heart rate in patients with ejection fraction < 40% from day 4 to day 30. The results indicate that: (1) the response of pre-ejection period/left ventricular ejection time ratio after increasing afterload may be a useful non-invasive method for the detection of left ventricular dysfunction in myocardial infarction patients; and (2) captopril adjuvant therapy as compared to thrombolysis, beta-blockers and nitrates alone, after phenylephrine administration, improves the left ventricular performance response in asymptomatic Q-wave post-infarction patients and beneficially affects heart rate. This effect is most pronounced in patients with ejection fraction < 40% whereas those with ejection fraction > or = 40% do not obtain clear benefit.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies